Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 13/20 | 0.34 |
| ▸ | BRAF | P15056 | 13/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HCK | P08631 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994797 | 0.95 | SYK (0.42) | SYKHSD11B1RAF1BRAFMTOR | |
| SCHEMBL23993202 | 0.92 | RAF1 (0.36) | SYKHSD11B1RAF1BRAFMTOR | |
| SCHEMBL30224920 | 0.92 | RAF1 (0.36) | SYKHSD11B1RAF1BRAFMTOR | |
| SCHEMBL23993461 | 0.90 | SYK (0.34) | SYKRAF1BRAFMTORPIK3CD | |
| SCHEMBL30224149 | 0.90 | PLAU (0.38) | SYKRAF1BRAFMTORPIK3CD | |
| SCHEMBL23992929 | 0.90 | PLAU (0.38) | SYKRAF1BRAFMTORPIK3CD | |
| SCHEMBL23994440 | 0.89 | PLAU (0.39) | SYKRAF1BRAFMTORPIK3CD | |
| SCHEMBL23994803 | 0.88 | SMPD3 (0.37) | SYKHSD11B1RAF1BRAFMTOR | |
| SCHEMBL30224460 | 0.88 | SMPD3 (0.37) | SYKHSD11B1RAF1BRAFMTOR | |
| SCHEMBL25005985 | 0.88 | RAF1 (0.33) | SYKHSD11B1RAF1BRAFMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | SYK 2578/4885HSD11B1 4354/4885RAF1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.